Sarah Holy, MD
Retina Specialist · San Antonio, TXNPI 1275514796
Payments from drug & device makers
Across 86 payments — averaging $8016.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$672K
- US Retina LLC$12K
- Alimera Sciences, Inc.$1K
- Genentech USA, Inc.$991
- Alcon$698
- AbbVie$358
- plus $3K from 18 others
What the payments were for
- Speaking & faculty fees$2682%
- Food & beverage$5,86433%
- Ownership interest$4,98328%
- Other$6,65237%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $671,855 |
| US Retina LLC | 11 | $11,635 |
| Alimera Sciences, Inc. | 12 | $1,169 |
| Genentech USA, Inc. | 13 | $991 |
| Alcon | 6 | $698 |
| AbbVie(2 entities) | 5 | $358 |
| Biotissue Holdings Inc. | 2 | $300 |
| Regeneron | 3 | $280 |
| Notal Vision, Inc. | 1 | $268 |
| Apellis Pharmaceuticals, Inc. | 3 | $256 |
| Astellas Pharma US Inc | 2 | $246 |
| Eyepoint US, Inc. | 3 | $173 |
| Biogen | 5 | $154 |
| Ocular Therapeutix, Inc. | 2 | $146 |
| Amgen | 1 | $122 |
| Optovue, Inc. | 1 | $120 |
| ANI Pharmaceuticals, Inc. | 1 | $112 |
| Regeneron Healthcare Solutions, Inc. | 1 | $103 |
| Rxsight Inc | 1 | $101 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Aerie Pharmaceuticals, Inc. | 1 | $98 |
| Novo Nordisk | 1 | $82 |
| Coherus Oncology, Inc. | 1 | $26 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$890
- YUTIQ$593
- VABYSMO$347
- OZURDEX$323
- Clareon$279
- Lucentis$242
- Syfovre$234
- EYLEA$226
- Prokera$176
- AmnioGraft$176
- SUSVIMO$140
- Centurion$134
- UPLIZNA$122
- Izervay$122
- XR$120
- DEXTENZA$118
- Constellation$109
- EYLEA HD$103
- RXSIGHT CONTACT LENS$101
- RXSIGHT INJECTOR CARTRIDGE$101
How this compares
$689,418 in reported general payments places this provider in the 90th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 83 | $2,817 |
| Brimonidine Tartrate | 16 | $1,278 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $707 |
| Latanoprost | 28 | $311 |
| Tobramycin | 64 | $301 |
| Timolol Maleate | 12 | $82 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in San Antonio
- Richard LaneSan Antonio$4.7M
- Timothy ClelandSan Antonio$534K
- Enchun LiuSan Antonio$99K
- Moises ChicaSan Antonio$64K
- Dianne BarrettSan Antonio$48K
- Duncan FriedmanSan Antonio$9K
- Thomas OeiSan Antonio$9K
- Lina MaroufSan Antonio$4K
- Abumere AkinwaleSan Antonio$3K
- Rushil RaoSan Antonio$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.